IGF-I is synthesized in the human and rat anterior pituitary glands. The present study was designed to clarify the growth-promoting action of IGF-I on mouse pituitary cells in a primary serum-free culture system. Proliferation of pituitary cells was detected by monitoring the cellular uptake of bromodeoxyuridine (BrdU). BrdU labelling in the nucleus was found in all types of secretory cells: corticotrophs, thyrotrophs, gonadotrophs (LH cells and FSH cells), somatotrophs and mammotrophs. IGF-I (75 ng/ml) stimulated the proliferation of corticotrophs and mammotrophs among the pituitary secretory cells. IGF-I receptor mRNA was detected in the cultured pituitary cells using reverse transcription (RT)-PCR, indicating that mouse pituitary cells expressed IGF-I receptors. Insulin (100 ng/ml) or IGF-I (7·5 ng/ml) failed to increase the percentage of BrdU-labelled cells. However, treatment with insulin (100 ng/ml) plus IGF-I (7·5 ng/ml) increased the percentage of BrdU-labelled cells in a synergistic-like manner. Genistein, a tyrosine kinase specific inhibitor, decreased the IGF-I-induced cell proliferation, indicating that IGF-I acts through IGF-I receptors. IGF-I mRNA was also detected in the cultured pituitary cells by RT-PCR, and its peptides were immunocytochemically detected. The present results demonstrate that all types of pituitary secretory cells have the ability to proliferate in our serum-free culture system. IGF-I synthesized in the pituitary gland may stimulate the growth of pituitary cells, in particular corticotrophs and mammotrophs, by an autocrine or paracrine mechanism.
Introduction
Several growth factors, for example insulin-like growth factor I (IGF-I), epidermal growth factor (EGF) and transforming growth factor-(TGF-), are produced in the human and rat pituitary glands (Webster & Scanlon 1991 , Renner et al. 1996 and may act locally within the gland. Several reports have indicated that rat pituitary IGF-I regulates GH transcription and secretion by an autocrine or paracrine mechanism (Yamashita & Melmed 1986 , Fagin et al. 1987 . Growth-promoting actions of IGF-I have been found in various tissues (Conover et al. 1985) . As is the case for pituitary tumour cells, IGF-I is also required for the growth of human adenoma cells (Renner et al. 1993 ) and rat GH 3 cells (Hayashi 1984) , and it stimulates the growth of mouse AtT-20 cells (Van Wijk et al. 1995) . The role of IGF-I in the growth of normal pituitary glands is not known. We found previously that insulin stimulated the proliferation of rat and mouse pituitary cells, particularly mammotrophs in vivo and in vitro , Takahashi & Osawa 1994 , Oomizu & Takahashi 1996 . IGF-I shares 43% amino acid sequence homology with proinsulin, and biological activities of IGF-I are similar to those of insulin. IGF-I receptors (type I receptors) and insulin receptors are localized in rat pituitary glands (Goodyer et al. 1984 , Bach & Bondy 1992 , Unger & Lange 1997 . Furthermore, insulin can bind to the IGF-I receptor, although with low affinity (Houslay & Wakelam 1988) .
The growth-promoting action of insulin on the pituitary cell may therefore be mediated through IGF-I receptors. The aim of the present study was to determine whether IGF-I regulates the proliferation of normal pituitary cells in a serum-free culture system.
The proliferation of pituitary cells was monitored by immunocytochemical detection of bromodeoxyuridine (BrdU) in the nucleus, and the pituitary secretory cell types of BrdU-labelled cells and IGF-I-containing cells were immunocytochemically determined. Expression of IGF-I mRNA and its receptor mRNA in cultured pituitary cells was studied by reverse transcription (RT)-PCR.
Insulin receptor and IGF-I receptor belong to the superfamily of receptors with tyrosine kinase activity. Genistein is a specific tyrosine kinase inhibitor, first described as an inhibitor of EGF receptors, pp60
v-src and pp110 gag-fes (Akiyama et al. 1987) . In this investigation, we examined whether genistein inhibited the IGF-I-or insulin-induced proliferation of pituitary cells. As a control, an equivalent dose of daidzein was added into the medium. Daidzein, similar in structure to genistein, does not inhibit the enzyme activity of tyrosine kinase (Akiyama et al. 1987) .
Materials and Methods

Animals
Two-month-old male mice of the ICR strain (CLEA Japan Inc., Osaka, Japan) were used. They were kept in a temperature-controlled animal room, and a commercial diet CE-7 (CLEA Inc.) and tap water were available ad libitum. All animal care and experiments were performed in accordance with the Guidelines of Animal Experimentation, Faculty of Science, Okayama University, Japan.
Isolation of pituitary cells
Pituitary cells were isolated according to the method of Oomizu & Takahashi (1996) . Briefly, anterior pituitaries were cut into small pieces with a sterile razor blade. The pieces were digested with trypsin (0·5%, w/v, DIFCO, Detroit, MI, USA) in Hanks' solution containing Hepes (HSH; 20 mM) and BSA (0·3% w/v, BSA) (HSH-BSA) at 37 C for 15 min. The fragments were incubated with DNase for 1 min and then with soybean trypsin inhibitor (1% w/v; Sigma, St Louis, MO, USA) in HSH-BSA at 37 C for 10 min. After being rinsed with Ca 2+ -Mg 2+ -free HSH-BSA, they were incubated in 2 mM EDTA-HSH solution and 1 mM EDTA-HSH solution for 5 and 15 min respectively. After gentle pipetting, dispersed cells were collected by centrifugation. Cell yield was calculated by cell counting with a haemocytometer, and cell viability was checked using trypan blue exclusion (usually more than 95%).
The isolated pituitary cells were suspended in a 1 : 1 mixture of Dulbecco's modified Eagle's medium and Ham's F12 medium without phenol red (DMEM/ F12 medium, Sigma) containing fetal calf serum (FCS, 10%, v/v) . They were seeded on poly--lysine (Sigma)-coated plastic coverslips (diameter 13 mm, Sumitomo, Tokyo, Japan) in 24 well tissue culture plates (Becton Dickinson, Lincoln Park, NJ, USA) at a density of 5 10 5 cells/ml per well. The culture was continued at 37 C in humidified atmosphere of 5% CO 2 and 95% air.
Cell treatment
After 3 days of pre-culture in DMEM/F12 medium containing 10% FCS to enhance cell attachment, the pituitary cells were cultured in serum-free DMEM/ F12 medium supplemented with hydrocortisone (100 µg/ l), tri-iodothyronine (400 ng/l), transferrin (10 mg/l), bovine glucagon (10 ng/ml), parathyroid hormone (200 ng/l) and sodium selenite (5 µg/l) for 5 days. Reagents of cell culture grade were obtained from Sigma.
Human recombinant IGF-I was obtained from Amersham International plc, Amersham, Bucks, UK and was added to the culture media at various concentrations (0·075-750 ng/ml) for 5 days. Insulin was stocked and diluted in culture medium according to the method described elsewhere (Shiraga et al. 1997) . The medium was changed every 2 days during these 5-day treatments. Each treatment was performed in triplicate, on plastic coverslips.
Immunocytochemical detection of cell proliferation and pituitary hormones
DNA-synthesizing cells and pituitary secretory cell types were determined by dual-labelling immunocytochemical detection of pituitary hormones and BrdU. For BrdU detection, BrdU solution (3 mg/ml) was added to the culture medium. After 3 h incubation in the BrdU solution, the cultured cells were fixed with Bouin's solution for 30 min at room temperature. Non-specific immunoreactivity was blocked by incubating the plastic coverslips with 1% low-fat dried milk (w/v) in 0·01 M PBS (pH 7·6) for 30 min at room temperature. The cells were then incubated with the monoclonal antibodies raised against BrdU (Amersham) for 1 h at room temperature in a humidified box. The cells were washed three times with 0·01 M PBS, and then incubated in peroxidase-conjugated anti-mouse immunoglobulin G (IgG) for 30 min at room temperature. After the plastic coverslips were again washed with 0·01 M PBS three times, the immunoreactivity of BrdU was detected using 3,3 -diaminobenzidine tetrahydrochloride (DAB) with nickel chloride as a chromogen. DAB (10 mg) was dissolved in 0·05 M phosphate buffer (30 ml), and three drops of nickel chloride (3%) and hydrogen peroxide (3%) solution were also added (Hsu & Soban 1982) . The DAB solution was applied to the cells for 1-5 min at room temperature. The BrdU-labelled nuclei were stained purplish blue. After detection of BrdU-labelled cells, pituitary-hormone producing cells were immunocytochemically stained by the avidinbiotin-peroxidase complex technique (Hsu et al. 1980 ) to identify secretory cell types of DNA-synthesizing cells. The plastic coverslips that had been already immunostained with the monoclonal antibodies raised against BrdU were treated with 0·3% hydrogen peroxide in absolute methanol for 20 min at room temperature to block peroxidase activity. After being washed three times with 0·01 M PBS, the cells were incubated for 1 h at room temperature in a humidified box with one of polyclonal antibodies raised against pituitary hormones : rabbit antipig adrenocorticotrophic hormone (ACTH; 1 : 2000, Advance, Tokyo, Japan), rabbit anti-rat thyroid hormonestimulating hormone (TSH ; 1 : 2000, IC-1, NIDDK, Bethesda, MD, USA), guinea pig anti-rat luteinizing hormone (LH ; 1 : 2500, IC-2, NIDDK), guinea pig anti-rat follicle-stimulating hormone (FSH ; 1 : 2000, IC-1, NIDDK), monkey anti-mouse growth hormone (GH; 1 : 2000, No. 35, NIDDK) and rabbit anti-mouse prolactin (PRL; 1 : 2000, Shikibo, Kusatsu, Japan). After the incubation, the cells were washed three times with 0·01 M PBS, and the second antisera (anti-rabbit IgG, anti-monkey IgG or anti-guinea pig IgG biotinylated antiserum, 1 : 200) were applied for 30 min. The cells were washed three times with 0·01 M PBS, and then the third reagent (avidin-biotin-peroxidase complex) was applied for 30 min at room temperature. The immunoreactivities of pituitary hormones were detected using DAB (10 mg) solution in 0·05 M Tris-HCl buffer (30 ml, pH 7·6) with added 1% hydrogen peroxide (150 µl). The DAB solution was applied to the cells for 1-5 min. The pituitary hormones were stained brown. The colour was easily distinguished from the purplish blue of the BrdU labelled nuclei as shown in Fig. 3 . The plastic coverslips were mounted on glass slides with Permount (Fisher Chemical, Fair Lawn, NJ, USA).
Immunostaining was abolished by omission of each primary antibody or by the use of primary antibodies (working dilution, 100 µl) preabsorbed with 10 µg of each highly purified pituitary hormone (ACTH, rat TSH, rat LH, rat FSH, rat GH, rat PRL) at 4 C for 24 h. The specificity of antibodies to mouse GH and PRL was also checked with the immunoblotting assay . To ascertain the validity of dual-labelling immunocytochemical detection, controls were performed by omitting either the antibody to BrdU or antibodies to pituitary hormones. Without the antibody to BrdU, immunostaining of the pituitary hormones was not altered. Without antibodies to pituitary hormones, immunostaining of BrdU was not altered.
Immunocytochemical detection of IGF-I-containing pituitary cells
Cultured pituitary cells were processed for immunocytochemistry as described above. The cells were incubated with the polyclonal antibodies raised against IGF-I (1 : 200, UB286, NIDDK) for 1 h at room temperature, washed with PBS and incubated with FITC-labelled anti-rabbit IgG in the dark for 1 h. To assess the specificity of IGF-I staining, the cells were incubated with PBS instead of the anti-IGF-I antibodies preabsorbed with recombinant human IGF-I (3·75 µg/ml diluted antibody solution) at 4 C for 24 h. No cells were stained in either of these controls.
Quantification of the immunolabelled cells
The cells were examined by light microscopy at a magnification of 600. The fields were scanned randomly across the coverslip to avoid overlap. In each field, immunopositive cells and immunonegative cells were counted; more than 1000 cells were examined on each coverslip. The percentages of BrdU-labelled cells were assessed by counting those cells that had a densely labelled (purplish blue) nucleus in entire cells. For each cell type, three coverslips were examined.
RT-PCR assay and Southern blot hybridization
Total RNA was prepared from the cultured pituitary cells using the method of Chomczynski & Sacchi (1987) . Eighty nanograms of the RNA was subjected to RT-PCR using a thermal cycler (GeneAmp PCR System 9600; Perkin Elmer, Forster City, CA, USA) and a Gene Amp EZ rTth RNA PCR kit (Perkin Elmer) according to the manufacture's instructions. Oligonucleotide primes for the IGF-I receptor and IGF-I are based upon the report by Ho et al. (1995) , and were synthesized by the Gibco BRL Custom Primers, Life Technologies Asia Pacific (Yokohama, Japan). The sequences of primers were as follows: IGF-I receptor 5 sense primer; 5 -ACTGACCTCATGCGCATGTGCTGG-3 , IGF-I receptor 3 antisense primer; 5 -CTCGTTCTTGCGG CCCCCGTTCAT-3 , IGF-I 5 sense primer; 5 -GGACCAGAGACCCTTTGCGGGG-3 , IGF-I 3 antisense primer; 5 -GGCTGCTTTTGTAGGCTTCAG TGG-3 . These primers generate PCR products of 345 and 210 bp for the IGF-I receptor and IGF-I respectively. The RT reaction was performed for 40 min at 60 C, and PCR cycling was performed with the following cycle profile: 94 C for 120 s, followed by 35 cycles of 94 C for 45 s and 60 C for 45 s. After the last cycle, the elongation step was extended by 7 min. RT-PCR products were separated by 2% agarose gel electrophoresis, stained with ethidium bromide, photographed under u.v. illumination and compared with a known standard (100 bp DNA Ladder, Gibco BRL, Gaithersburg, MD, USA) for size determination. To verify that the bands obtained by PCR were generated from amplification of IGF-I and IGF-I receptor cDNAs, they were transferred onto Hybond N + (Amersham) and subjected to Southern blotting. Preparation and detection of probes were carried out using an ECL Random Prime and Detection system, version II (Amersham) according to the manufacture's instructions. Blots were exposed to Hyperfilm-ECL (Amersham). As negative controls, PCRs were performed with RNA that had not been reverse transcribed and samples lacking RNA in the RT reaction.
Probe for Southern blot hybridization
DNA fragments encoding a part of the mouse IGF-I receptor were obtained from total RNA prepared from the uteri of ICR mice by RT-PCR using the primers described above. The cDNA fragment was subcloned into pGEM3Zf(+) and subjected to sequencing. Dideoxynucleotide sequencing was performed using fluorescent primers and an automated DNA sequencer. One clone, designated as pcrmIGF-IR, was 354 bp in length and encoded an 118 amino acid protein, sharing 92·6 and 88·1% identity with rat or human IGF-I receptors respectively. We concluded that pcrmIGF-IR was a cDNA encoding a part of the mouse IGF-I receptor and used it as a probe. The nucleotide sequence of pcrmIGF-IR will appear in the DDBJ, EMBL and GenBank nucleotide sequence data bases with the accession number AB006442. The cDNA clone for the mouse IGF-I (pmigf1-2) was 720 bp in length and obtained from ATCC (Rockville, MD, USA).
Genistein treatment
Insulin receptors and IGF-I-receptors belong to the superfamily of receptors with tyrosine kinase activity. We studied the effects of genistein, a specific tyrosine kinase inhibitor, on the proliferation of the pituitary cells, to determine whether the IGF-I-or insulin-induced proliferation of pituitary cells was regulated through IGF-I or insulin receptors. Pituitary cells were treated with IGF-I (75 ng/ml) or insulin (10 µg/ml) for 5 days in serum-free culture. Genistein (1-50 µM, Wako Pure Chemicals Industries, Osaka, Japan) was added to the medium for 5 h on the last day. As a control, an equivalent dose of daidzein was added to the medium. Genistein and daidzein were diluted in the culture medium according to the method described by Buckley et al. (1993) .
Statistics
The percentages of BrdU-labelled cells are presented as the mean ... Data were analysed by analysis of variance, followed by Duncan's multiple range tests. Differences of P<0·05 were considered statistically significant.
Results
Effects of IGF-I on proliferation of pituitary cells
Dissociated pituitary cells were maintained in serumsupplemented medium (10% FCS) for 3 days to promote the attachment of cells to the plastic coverslips, and then transferred to serum-free medium. The nucleus of DNAsynthesizing pituitary cells was labelled with BrdU, which was detected immunocytochemically. Depletion of the FCS resulted in a decrease in the percentages of BrdUlabelled cells to about one-fifth of the levels in the 10% serum-supplemented condition 2 days later (serumsupplemented, 5·36 0·23%; serum-depleted, 1·09 0·26%), indicating that the FCS contained growthpromoting factors for pituitary cells.
Pituitary cells were treated with 75 ng/ml IGF-I for 5 days, and the time-course of IGF-I action on the proliferation of pituitary cells was studied (Fig. 1) . IGF-I treatment significantly increased the percentages of BrdUlabelled cells compared with control treatment at days 2, 4 and 5 (all P<0·01). In a separate experiment, pituitary cells were treated with IGF-I (75 mg/ml) for 5 days after they had been maintained in serum-free culture for 3 days. IGF-I treatment also significantly increased the proportion of these cells that were BrdU-labelled, compared with control treatment (IGF-I treated, 3·6 0·26%; control, 1·4 0·13%).
Pituitary cells were cultured with various concentrations of IGF-I (0·075-750 ng/ml) for 5 days. The percentages of BrdU-labelled cells were greater than those in control cultures when 75 and 750 ng/ml IGF-I were added to the culture media (P<0·01, P<0·05 respectively; Fig. 2 ).
Immunocytochemical detection of pituitary secretory cell types of DNA-synthesizing cells
Pituitary cell types of BrdU-labelled cells were immunocytochemically determined using antibodies raised against pituitary hormones. BrdU was detected in subsets of all the hormone-producing cells. Figure 3 illustrates BrdUlabelled corticotrophs and mammotrophs. These observations indicate that pituitary secretory cells had the ability to proliferate even in serum-free culture.
The percentages of BrdU-labelled cells were studied in pituitary cells treated with IGF-I (75 ng/ml; Fig. 4) . Corticotrophs were most abundant among BrdU-labelled cells, irrespective of IGF-I treatment. IGF-I significantly stimulated BrdU-labelling (approximately twofold) in corticotrophs and mammotrophs, but not in any other subsets of pituitary cells (Fig. 4) . BrdU-labelled corticotrophs accounted for 0·86% of total corticotrophs in controls, and for 2·1% in the IGF-I-treated group. BrdU-labelled mammotrophs accounted for 0·46% of total mammotrophs in controls, and for 0·87% in the IGF-I-treated group.
Effect of insulin and IGF-I on proliferation of pituitary cells
Our previous study demonstrated that a concentration of 10 µg/ml insulin stimulated the proliferation of pituitary cells, in particular mammotrophs, in vitro (Oomizu & Takahashi 1996) . Effects of insulin and IGF-I were compared to determine whether the action of insulin in greater concentrations was mediated by IGF-I receptors. In the present study, a concentration of 75 ng/ml IGF-I significantly increased the percentage of BrdU-labelled cells (Fig. 2) . Insulin (100 ng/ml) or IGF-I (7·5 ng/ml) failed to increase the percentages of BrdU-labelled cells (Fig. 5 ). Treatment with insulin (100 ng/ml) plus IGF-I (7·5 ng/ml), however, significantly increased the percentage of BrdU-labelled cells (3·4 0·3%) to the level attained with 10 µg/ml insulin treatment (3·3 0·2%). Thus, when insulin and IGF-I were both added to cultures, a synergistic-like effect was observed.
Detection of IGF-I receptor mRNA and IGF-I mRNA in pituitary cells
IGF-I receptor mRNA and IGF-I mRNA could not be detected in total RNA from the cultured pituitary cells by northern blot analysis (data not shown). RT-PCR was also performed to determine whether they were present in the cultured pituitary cells. Amplification for IGF-I receptor and IGF-I gene gave single bands in ethidium bromidestained gels (Fig. 6) . A 345-bp product and a 210-bp product corresponded respectively to amplified cDNAs of IGF-I receptor and IGF-I, judging from size of the products. In PCR without RT, no PCR products were found in either amplification. Southern blot analysis using IGF-I receptor cDNA and IGF-I cDNA probes confirmed that the RT-PCR bands corresponded to IGF-I mRNA and IGF-I receptor mRNA (Fig. 6) . These results indicate that IGF-I mRNA and its receptor mRNA were expressed in the cultured pituitary cells.
Immunoreactive IGF-I was detected within the cytoplasm of some cultured pituitary cells. IGF-I-containing cells were oval, elongated or irregular in shape, and medium in size. They were not fibroblast-like cells. These observations suggest that some of pituitary secretory cells synthesize and probably secrete IGF-I in primary culture (Fig. 7) .
Effect of genistein on the proliferation of pituitary cells
Genistein at concentrations of 5 µM and greater significantly inhibited the insulin (10 µg/ml)-induced increase in the percentage of BrdU-labelled cells compared with treatment with daidzein in a corresponding concentration (Fig. 8) . IGF-I-induced proliferation of pituitary cells was also inhibited by genistein at a concentration of 25 µM (P<0·05, Fig. 8 ).
Discussion
The present study clearly demonstrated that the cultured pituitary cells produced six pituitary hormones, and all subsets of secretory cells had the ability to proliferate in primary culture. IGF-I treatment stimulated proliferation of corticotrophs and mammotrophs, but not that of the other types of secretory cells. Serum depletion decreased the proliferation of pituitary cells, indicating that FCS contained growth-promoting factors. However, when cultured pituitary cells were kept in the serum-free culture for 3 days, and then treated with IGF-I for another 5 days, the growth-stimulatory effect of IGF-I on corticotrophs and mammotrophs was still evident. These findings indicate that IGF-I is a growth-promoting factor specific for corticotrophs and mammotrophs.
Insulin stimulated the proliferation of pituitary cells, particularly mammotrophs in vivo and in vitro, and insulin has been shown to be necessary for oestrogen-induced pituitary growth in vivo , Takahashi & Osawa 1994 , Oomizu & Takahashi 1996 . IGF-I shares structural and functional similarities with insulin. Both IGF-I receptors and insulin receptors are localized in rat pituitary glands (Goodyer et al. 1984 , Bach & Bondy 1992 , Unger & Lange 1997 . Insulin stimulated the proliferation of pituitary cells in vitro at a minimum concentration of 1 µg/ml (Oomizu & Takahashi 1996) . In contrast, IGF-I was effective from a concentration of 75 ng/ml. Thus, compared with IGF-I, an approximately 10-fold greater concentration of insulin was required to stimulate the proliferation of pituitary cells. The IGF-I receptor binds IGF-I with high affinity, and binds insulin with low affinity (Houslay & Wakelam 1988) . The growth-promoting action of insulin on the pituitary cell may be mediated through IGF-I receptors. In the present study, treatment with either IGF-I (7·5 ng/ml) or insulin (100 ng/ml) alone failed to increase the percentage of BrdU-labelled cells, but combined treatment with IGF-I (7·5 ng/ml) plus insulin (100 ng/ml) produced a significant increase. This suggests the possibility that low concentrations of insulin enhance the response of pituitary cells to IGF-I and that, at higher concentrations, insulin binds IGF-I receptor, triggering cell proliferation. The IGF-I receptormediated system and the insulin receptor-mediated system may work together in the regulation of pituitary growth process. Recently, Unger & Lange (1997) demonstrated immunocytochemically that insulin receptors were located in -endorphin-synthesizing cells and that IGF-I receptors were present in gonadotrophs in the rat pituitary gland. They did not detect IGF-I receptors in corticotrophs and mammotrophs, which is in contrast to our present finding that IGF-I stimulated the proliferation of both cells. The reason for this discrepancy is currently not clear.
IGF-I is synthesized in the rat pituitary gland (Bach & Bondy 1992) . IGF-I mRNA was detected in the mouse pituitary cells using RT-PCR, and IGF-I peptide was detected immunocytochemically in mouse pituitaries using anti-human IGF-I serum, although the particular secretory cell types of the IGF-I-synthesizing cells remain to be determined. These findings are in agreement with several studies demonstrating that IGF-I and its mRNA were detected in human and rat pituitary cells (Yamaguchi et al. 1990 , Alberti et al. 1991 . In the human pituitaries, IGF-I-containing cells showed a dispersed distribution within the glands (Ren et al. 1994) . In rat pituitaries, folliculo-stellate cells synthesize IGF-I (Bach & Bondy 1992) , but the possibility cannot be excluded that some other types of pituitary cells synthesize IGF-I. Pituitary tumour GH 3 cells express IGF-I mRNA (Fagin et al. 1987 , Renner et al. 1993 . These findings strongly support the possibility that proliferation of pituitary cells, including tumour cells, may be regulated by IGF-I secreted from pituitary cells by an autocrine or paracrine mechanism, as already suggested by Renner et al. (1993) . To examine this possibility, it will be necessary to study further the regulatory mechanism of pituitary IGF-I synthesis and release.
In the ovine fetal pituitary, IGF-I increased corticotrophin-releasing hormone binding, but did not influence ACTH secretion (Lü et al. 1995) . The present study revealed new pituitary IGF-I action on the growth of corticotrophs. Childs et al. (1995) found that proliferation of corticotrophs was stimulated by EGF, which was involved in stress responses such as cold stress . Corticotrophic functions seemed to be modified by pituitary IGF-I and EGF through a paracrine mechanism.
Several studies have indicated that the action of oestrogen on cell proliferation is indirect and is mediated by autocrine or paracrine growth factors (Sirbasku 1978) . Oestrogen receptors are expressed in all subsets of pituitary secretory cells, including corticotrophs and mammotrophs (Kikuta et al. 1993) . Oestrogen stimulates the proliferation of pituitary cells, particularly mammotrophs (Lloyd et al. 1975 , Takahashi et al. 1984 , and the amount of IGF-I mRNA, IGF-I-binding and binding proteins in the rat pituitary gland has been shown to be increased by oestrogen treatment (Michels et al. 1993) . The findings of the present study, together with these previous observations, suggest that the oestrogen-induced pituitary growth (mammotrophs) is mediated through the pituitary IGF-I system.
Genistein, a specific tyrosine kinase inhibitor (Akiyama et al. 1987) , inhibits tyrosine kinase-mediated mitogenesis in Nb2 lymphoma cells (Buckley et al. 1993) . The IGF-Ior insulin-induced proliferation of pituitary cells was blocked by genistein, but not by daidzein. IGF type I receptors and insulin receptors have tyrosine kinase activity. Our present findings indicate that IGF-I or insulin added to the medium induces the cell proliferation through IGF-I receptors or insulin receptors.
In conclusion, the present study indicates that mouse pituitary IGF-I is in involved in the growth of corticotrophs and mammotrophs. Identification of the IGF-Iproducing cells in the mouse pituitary gland remains to be undertaken.
